We present an overview of a number of key clinical studies in infiltrating gliomas presented at the 2013 Society for Neuro-Oncology and World Federation of Neuro-Oncology joint meeting. This review focuses on efficacy results, including quality of life studies, from larger clinical trials in both high- and low-grade infiltrating gliomas.
SulmanE., WonM., EzhiliarasamR., SunP., BlumenthalD., VogelbaumM., ColmanH., JenkinsR., ChakravartiA., JerajR., BrownP., JaeckleK., SchiffD., DignamJ., AtkinsJ., BrachmanD., Werner-WasikM., GilbertM., MehtaM., AldapeK.: A molecular predictor of response to bevacizumab based on analysis of RTOG 0825, a phase III trial comparing chemoradiation with and without bevacizumab in patients with newly diagnosed glioblastoma. Abstract OM-067. Neuro Oncol, 15(Suppl 3): 152, 2013.
3.
ChinotO.L., WickW., MasonW., HenrikssonE., SaranF., NishikawaR., CarpentierA.F., Hoang-XuanK., KavanP., CerneaD., BrandesA.A., HiltonM., KerloeguenY., GuijarroA., CloughesyT.: Final efficacy and safety results from AVAglio, a phase III trial of bevacizumab (BEV) plus temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma. Abstract NO-031. Neuro Oncol, 15(Suppl 3): 105–106, 2013.
4.
HerrlingerU., SchaferN., SteinbachJ., WeyerbrockA., HauP., GoldbrunnerR., KohnenR., UrbachH., StummerW., GlasM.: Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: updated results from the multicenter GLARIUS trial. Abstract MR-011. Neuro Oncol, 15(Suppl 3): 77, 2013.
5.
VredenburghJ.J., CloughesyT., SamantM., PradosM., WenP.Y., MikkelsenT., SchiffD., AbreyL.E., YungW.K., PaleologosN., NicholasM.K., JensenR., DasA., FriedmanH.S.: Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist, 15: 1329–1334, 2010.
6.
TaalW., OosterkampH., WalenkampA., BeerenpootW., HanseM., ButerJ., HonkoopA., BoermanD., de VosF., JansenR., van der BerkmortelF., BrandsmaD., EntingR., KrosJ., BrombergJ., van HeuvelI., SmitsM., van der HoltR., VernhoutR., van den BentM.: A randomized phase II study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. Abstract MR-035. Neuro Oncol, 15(Suppl 3): 83–84, 2013.
7.
OmuroA., AbreyL., RaizerJ., PaleologosN., ForsythP., De AngelisL., KaleyT., LouisD., CairncrossJ.G., MatasarM., MehtaJ., GrimmS., MoskowitzC., SauterC.: Temozolomide followed by high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) for newly diagnosed anaplastic oligodendroglioma (AO): can radiotherapy be deferred? Abstract NO-108. Neuro Oncol, 15(Suppl 3): 125, 2013.
8.
SmithJ.S., ChangE.F., LambornK.R., ChangS.M., PradosM.D., ChaS., TihanT., VandenbergS., McDermottM.W., BergerM.S.: Role of extent of resection in the long-term outcome of hemispheric low-grade gliomas. J Clin Oncol, 26: 1338–1345, 2008.
9.
CapelleL., FontaineD., MandonnetE., TaillandierL., GolmardJ.L., BauchetL., PalludJ., PerruziP., BaronM.H., KujasM., GuyotatJ., GuillevinR., FrenayM., TaillibertS., ColinP., RigauV., VandenbosF., PinelliC., DuffauH., French Reseau d'Etude des Gliomes: Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg, 118: 1157–1168, 2013.
10.
StummerW., PichlmeierU., MeinelT., WiestlerO.D., ZanellaF., ReulenH.J., ALA-Glioma Study Group: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 7: 392–401, 2006.
11.
De Witt HamerP.C., RoblesS.G., ZwindermanA.H., DuffauH., BergerM.S.: Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol, 30: 2559–2565, 2012.
12.
KuhntD., GanslandtO., SchlafferS.M., BuchfelderM., NimskyC.: Quantification of glioma removal by intraoperative high-field magnetic resonance imaging: an update. Neurosurgery, 69: 852–862, 2011.
13.
JakolaA.S., MyrmelJ.S., KlosterR., TorpS.H., LindalS., UnsgardG., SolheimO.: Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 308: 1881–1888, 2012.
14.
BrownP.: Initial results of RTOG 9802; will this be EORTC 26951/RTOG 9402 redux?SNO presentation, 2013.
15.
BaumertB.: The international EORTC/NCICCTG/TROG/MRC-CTU low-grade glioma trial: temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) LGG. SNO presentation, 2013.
16.
WefelJ., PughS., ArmstrongT., GilbertM., WonM., WendlandM., BrachmanD., BrownP., CrockerI., RobbinsH.I., LeeR.J., MehtaM.: Longitudinal analysis of neurocognitive outcomes in patients with glioblastoma (GBM). Abstract NC-021. Neuro Oncol, 15(Suppl 3): 97, 2013.
17.
ArmstrongT.S., WonM., WefelJ.S., GilbertM.R., PughS., WedlandM.M., BrachmanD.G., BrownP.D., CrockerI.R., RobbinsH.I., LeeR.J., MehtaM.: Comparative impact of tumor and treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Abstract SM-003. Neuro Oncol, 15(Suppl 3): 226, 2013.
18.
TaphoornM.J.B., HenrikssonR., BottomleyA., CloughesyT., WickW., MasonW., SaranF., NishikawaR., RaveloA., HiltonM., ChinotO.L.: Health-related quality of life (HRQoL) analyses in the AVAglio study, a randomized, placebo-controlled phase III trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma. Abstract SM-029. Neuro Oncol, 15(Suppl 3): 232, 2013.
19.
FisherB., ChenH., MacdonaldD., LesserG., CoonsS., BrachmanD., RyuS., Werner-WasikM., BaharyJ.P., ChakravartiA., MehtaM.: RTOG 0424: Phase II study of a temozolomide (TMZ)-based chemo-radiotherapy (RT) regimen for high risk low-grade gliomas (LGGs): preliminary results including quality of life (QOL) and neurological function (NCF). Abstract MR-009. Neuro Oncol, 15(Suppl 3): 77, 2013.
20.
FriedmanH.S., PradosM.D., WenP.Y., MikkelsenT., SchiffD., AbreyL.E., YungW.K., PaleologosN., NicholasM.K., JensenR., VredenburghJ., HuangJ., ZhengM., CloughesyT.: Bevacizumab alone or in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 27: 4733–4740, 2009.
21.
KreislT.N., KimL., MooreK., DuicP., RoyceC., StroudI., GarrenN., MackeyM., ButmanJ.A., CamphausenK., ParkJ., AlbertP.S., FineH.A.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol, 27: 740–745, 2009.
